Remifentanil (Ultiva™), a fentanyl derivative, is an ultra-short acting, nonspecific esterase-
metabolised, selective μ-opioid receptor agonist, with a pharmacodynamic profile typical of …

Anesthetic goals for procedures involving resections close to the motor cortex include
immobility, analgesia, and a level of consciousness that allows for the ability to follow motor …

Background The purpose of this study was to investigate the in vivo pharmacodynamics and
the pharmacodynamic interactions of remifentanil and its major metabolite, GR90291, in a …

Over the past 30 yr, there have been marked improvements in the opioids available to
clinicians. The major emphasis in the development of opioids has been increasing potency …

Background: Opioid agonists have been implicated in neuroprotection from hypoxic injury
through regulating mitogen-activated protein kinases and cytokines. We determined the …

Aim. Remifentanil hydrochloride is an ultra-short acting µ-opioid receptor agonist. This study
compared the use of remifentanil with that of fentanyl during elective supratentorial …

Remifentanil is a new opioid in the fentanyl family. Developed and marketed by Glaxo
Wellcome Inc., it was approved by the US Food and Drug Administration in July 1996 and …

Purpose To compare the quality of analgesia provided by a remifentanil-based analgesia
regime with that provided by a fentanyl-based regime in critically ill patients. Methods This …

Background Remifentanil is an esterase-metabolized opioid with a rapid clearance. The aim
of this study was to contrast the pharmacokinetics and pharmacodynamics of remifentanil …

Study Objective: To determine if remifentanil would offer a superior hemodynamic and
recovery profile compared to the current standard of care, which implements a fentanyl …